Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 53, 2019
Previous Article Next Article

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Author affiliations

Abstract

Despite their attractive properties, internal targeted alpha therapies using 223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra2+ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra2+ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona, the connection to other targeting (bio)macromolecules is possible.

Graphical abstract: A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Back to tab navigation

Supplementary files

Article information


Submitted
03 Apr 2019
Accepted
04 Jun 2019
First published
04 Jun 2019

Chem. Commun., 2019,55, 7631-7634
Article type
Communication

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

M. Gott, P. Yang, U. Kortz, H. Stephan, H. Pietzsch and C. Mamat, Chem. Commun., 2019, 55, 7631
DOI: 10.1039/C9CC02587A

Social activity

Search articles by author

Spotlight

Advertisements